3 studies found for:    12727920 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
Conditions: Pancreas Cancer;   Ovarian Cancer;   Melanoma;   Sarcoma
Intervention: Drug: Regorafenib
2 Active, not recruiting 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Drug: Dovitinib
3 Terminated Temodar and Sutent as Therapy for Melanoma
Condition: Metastatic Malignant Melanoma
Intervention: Drug: Temozolomide and SU11248

Indicates status has not been verified in more than two years